Extended efficacy and safety data
Tumor Shrinkage after 8 weeks treatment with arfolitixorin
Isofol presented promising patient data from the first 19 patients in January 2019. Data showed early tumor shrinkage (8 weeks of treatment), defined as a decrease greater than 20% of baseline tumor size, in 47% of patients (9/19) and clinical benefit. of treatment in 89% of patients (17/19), see graph below.
Overall Response Rate after up to 32 weeks treatment with arfolitixorin
In May 2019 preliminary response assessment data from 19 patients treated for up to 32 weeks showed a best overall response rate (ORR) in 58 % of patients (11/19). These patients were treated with the selected dose regimen of 120 mg/m2 arfolitixorin and 5-fluorouracil (5-FU) with either irinotecan or oxaliplatin (ARFIRI/ARFOX). ORR is defined as a greater than 30 % reduction in tumor size from baseline.